SGMO
HEALTHCARESangamo Therapeutics Inc
$0.11+0.04 (+33.84%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SGMO Today?
No stock-specific AI insight has been generated for SGMO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.10$0.77
$0.11
Fundamentals
Market Cap$74M
P/E Ratio—
EPS$-0.44
Dividend Yield—
Dividend / Share—
ROE-28.9%
Profit Margin—
Debt / Equity—
Trading
Volume44.6M
Avg Volume (10D)—
Shares Outstanding414.3M
SGMO News
20 articles- Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)Yahoo Finance·Apr 30, 2026
- Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB marketAdvfn·Apr 29, 2026
- Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture MarketYahoo Finance·Apr 29, 2026
- Sangamo Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 31, 2026
- Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ...Yahoo Finance·Mar 31, 2026
- Sangamo Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 31, 2026
- Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial ResultsYahoo Finance·Mar 30, 2026
- Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 26, 2026
- Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 24, 2026
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings CallYahoo Finance·Mar 19, 2026
- Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 12, 2026
- Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseYahoo Finance·Mar 9, 2026
- Should FDA Accelerated Approval Pathway for ST-920 Gene Therapy Data Require Action From Sangamo Therapeutics (SGMO) Investors?Yahoo Finance·Feb 4, 2026
- Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026Yahoo Finance·Feb 3, 2026
- Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten OfferingYahoo Finance·Feb 3, 2026
- How The Pulled Price Target Is Reshaping The Story For Sangamo Therapeutics (SGMO)Yahoo Finance·Jan 23, 2026
- Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline UpdateYahoo Finance·Jan 12, 2026
- Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseYahoo Finance·Dec 18, 2025
- How the Narrative Surrounding Sangamo Therapeutics Is Shifting After New Regulatory and Valuation SignalsYahoo Finance·Dec 12, 2025
- Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsightYahoo Finance·Dec 3, 2025
All 20 articles loaded
Price Data
Open$0.15
Previous Close$0.18
Day High$0.20
Day Low$0.11
52 Week High$0.77
52 Week Low$0.10
52-Week Range
$0.10$0.77
$0.11
Fundamentals
Market Cap$74M
P/E Ratio—
EPS$-0.44
Dividend Yield—
Dividend / Share—
ROE-28.9%
Profit Margin—
Debt / Equity—
Trading
Volume44.6M
Avg Volume (10D)—
Shares Outstanding414.3M
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic drugs that transform the lives of patients using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company is headquartered in Brisbane, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—